Cellectar BioSciences

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cellectar BioSciences reports strong Q1 results and eyes FDA submission

Cellectar BioSciences is well-positioned with strong financial backing and promising product developments. Challenges include financial losses, pricing strategy, and market competition. Opportunities lie in upcoming data releases, FDA submission, and global partnerships.

Cellectar BioSciences reports strong Q2 performance and prepares for NDA submission

Cellectar BioSciences showcased strong financial performance and promising trial results in Q2 2024.
While facing challenges in financial restatements and analyst inquiries, the company is progressing well with NDA preparations.
The company's confidence in the NDA filing, supported by robust data, highlights growth opportunities in addressing unmet medical needs.

Cellectar BioSciences excels in Q3 with strong data and growth opportunities

Cellectar BioSciences showcased strong performance in the CLOVER-WaM study and financial stability with a cash position of $34.3 million.
The company's focus on iopofosine I 131's potential in WM treatment and strategic collaborations highlight promising growth opportunities.
However, challenges lie in addressing FDA confirmatory studies, managing funding needs, and balancing research efforts for solid tumors and WM treatment.
Overall, Cellectar's value proposition remains strong, with upcoming product launches and a clear commercialization strategy in place.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FLORHAM PARK, N.J., Jan.  07, 2020  (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it has appointed Dr. Igor Grachev as Chief Medical Officer.

Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer

FLORHAM PARK, N.J., Jan.  06, 2020  (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to CLR 131 in Lymphoplasmacytic Lymphoma (LPL). CLR 131 is the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate currently in a Phase 2 clinical study in relapsed or refractory select B-cell lymphomas, including Lymphoplasmacytic Lymphoma (LPL).

Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)

30% overall response rate seen with an average progression free survival of 4.5 months and an acceptable and expected safety profile

Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study

FLORHAM PARK, N.J., Dec.  09, 2019  (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the presentation of fractionated dosing data in 19 patients with relapsed/refractory multiple myeloma. Dr. Sikander Ailawadhi, M.D., Associate Professor, Division of Hematology/Oncology at Mayo Clinic Florida, presented the data in an oral presentation at the 61st Annual American Society of Hematology (ASH) meeting.

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference

FLORHAM PARK, N.J., Oct.  17, 2019  (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a poster presentation at the upcoming 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, being held from October 26 – 30, 2019 in Boston, MA.

Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston

Data showed durable clinical responses, including a 33% overall response rate (ORR) and 16.6% complete response (CR) Data showed durable clinical responses, including a 33% overall response rate (ORR) and 16.6% complete response (CR)

Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress

FLORHAM PARK, N.J., Sept.  24, 2019  (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the European Commission has awarded CLR 131 orphan designation for the treatment of multiple myeloma.

Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma

Data presented at the 17th International Myeloma Workshop

Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

FLORHAM PARK, N.J., Sept.  04, 2019  (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a late-breaker poster presentation at the upcoming 17th International Myeloma Workshop being held in Boston, Massachusetts from September 12-15, 2019. The data will focus on the activity of CLR 131 in a Phase 1, dose escalation study of patients with relapsed or refractory multiple myeloma.

Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop

Amarin Corporation Plc

BioMarin Pharmaceutical

GW Pharmaceuticals

Sanofi

The biotechnology space is an exciting one with incredible potential for investors.

5 Biotech Stocks With Near-Term Catalysts Ahead

News for Cellectar BioSciences Stock (CLRB)